Last reviewed · How we verify

oral polio vaccine + information

Bandim Health Project · FDA-approved active Biologic

Oral polio vaccine stimulates the immune system to produce antibodies against poliovirus types 1, 2, and 3, providing protection against poliomyelitis infection.

Oral polio vaccine stimulates the immune system to produce antibodies against poliovirus types 1, 2, and 3, providing protection against poliomyelitis infection. Used for Prevention of poliomyelitis (polio) in infants and children, Routine immunization against poliovirus in endemic and non-endemic regions.

At a glance

Generic nameoral polio vaccine + information
SponsorBandim Health Project
Drug classLive attenuated vaccine
TargetPoliovirus types 1, 2, and 3
ModalityBiologic
Therapeutic areaImmunology / Infectious Disease
PhaseFDA-approved

Mechanism of action

The vaccine contains live attenuated (weakened) poliovirus strains that replicate in the intestinal tract, triggering both mucosal and systemic immune responses. This generates neutralizing antibodies and cellular immunity against wild-type poliovirus, preventing infection and transmission. The oral route allows for intestinal immunity development, which is particularly important for blocking fecal-oral transmission.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: